The article also states that BP said “The timing of the correspondence coincides with refreshed leadership at the newly formed Office of Therapeutic Products (OTP) within CBER at the FDA and the release of draft industry guidance for demonstrating effectiveness in one adequate, well controlled clinical investigation with confirmatory evidence.” May be this time they are going to finally do the right thing with new leadership at OTP?
The article also states that BP said “The timing of the...
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |